Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · SUDEEPPHRM

SUDEEPPHRM

HealthcarePharmaceuticals & Biotechnology₹13571 cr market cap
₹1212.10 ▲ +0.82% today As of 19 Nov 2026
52-week low ₹530.0052-week high ₹1344.20

-10.6% from the 52-week high · +126.8% above the low

Sudeep Pharma Ltd manufactures pharmaceutical formulations and health care products for domestic and international markets. The company produces tablets, capsules, syrups, and specialized formulations. Its operations cover research, development, quality control, and regulatory compliance. By delivering safe and effective products, it contributes to healthcare solutions across multiple therapeutic segments.

The short version. SUDEEPPHRM reported revenue of ₹197 crore for Sep 2026, up 20.9% from a year earlier. Net profit was ₹52 crore (up 13.0% year on year). Return on equity was 19.6% in Mar 2026. Promoter holding was 76.15% in Sep 2026, up 0.00 points over 5 quarters.

1 · The price

How has the stock traded?

SUDEEPPHRM trades 10.6% below its 52-week high and 126.8% above its 52-week low.

Change over period: —

1M+19.8%
3M+4.0%
6M+84.9%
1Y—

2 · The business

Is it growing?

Sales, year on year+20.9%

Sep 2026 revenue of ₹197 cr.

Profit, year on year+13.0%

Sep 2026 net profit of ₹52 cr.

Net margin26.3%

1.8 pts lower than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025
Revenue197158182172163
Net profit5241494846
Net margin %26.325.626.827.628.1
EPS (₹)4.593.594.334.224.05

Annual

FY2026
Revenue642
Net profit173
Net margin %26.9
EPS (₹)15.31

3 · The quality

How well does it turn capital into profit?

Return on equity was 19.6% in Mar 2026; debt to equity is 0.17.

Profitability · 1 years

Returns and margins

Mar 2026
Return on equity %19.6
Return on capital %24.2
EBITDA margin %37.3
Net margin %25.8

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
Debt to equity0.17
Interest cover31.0x
Current ratio3.09
P/E ratio72.3

4 · The owners

Who holds it, and are they adding?

Promoter holding76.15%

Unchanged over 5 quarters.

Foreign institutions2.93%

Up 1.39 pts over 5 quarters.

Domestic institutions14.05%

Down 0.71 pts over 5 quarters.

Mutual fund schemes37

+16 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter76.1576.1576.1576.1576.150.0
FII1.541.671.551.812.93+1.39
DII14.7617.618.1115.6514.05-0.71
Public7.544.584.186.396.87-0.67

Mutual fund holdings · Oct 2026

37 schemes hold this stock

21 the month before.

  • SBI Comma Fund6.35% of NAV
  • SBI Healthcare Opportunities Fund2.39% of NAV
  • EDELWEISS RECENTLY LISTED IPO FUND2.37% of NAV
  • THE WEALTH COMPANY SMALL CAP FUND1.35% of NAV
  • PGIM INDIA SMALL CAP FUND1.22% of NAV
  • SBI MNC Fund1.2% of NAV
  • SBI RETIREMENT BENEFIT FUND - AGGRESSIVE PLAN1.16% of NAV
  • UTI - Healthcare Fund0.97% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for SUDEEPPHRM are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about SUDEEPPHRM

What is the SUDEEPPHRM share price?

SUDEEPPHRM (SUDEEPPHRM) last closed at ₹1,212.10, up 0.82% on the day. Its 52-week range is ₹530.00 to ₹1,344.20.

What is the market cap of SUDEEPPHRM?

SUDEEPPHRM has a market capitalisation of about ₹13,571 crore. Its price-to-earnings ratio is 72.3.

How are SUDEEPPHRM's latest results?

SUDEEPPHRM reported revenue of ₹197 crore for Sep 2026, up 20.9% from a year earlier. Net profit was ₹52 crore (up 13.0% year on year). Return on equity was 19.6% in Mar 2026. Promoter holding was 76.15% in Sep 2026, up 0.00 points over 5 quarters.

Who owns SUDEEPPHRM?

As of Sep 2026, shareholding was: Promoter 76.15%, FII 2.93%, DII 14.05%, Public 6.87%.

How many mutual funds hold SUDEEPPHRM?

37 mutual fund schemes held SUDEEPPHRM in October 2026. That compares with 21 the month before.

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.